Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
about
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studySearching for the delta: 5-aminosalicylic Acid therapy for Crohn's diseaseIntestinal absorption of water-soluble vitamins in health and diseasePneumocystis carinii activates the NF-kappaB signaling pathway in alveolar epithelial cells.Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to knowEffect of folic acid on methotrexate induction of sulfotransferases in rats.Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?Pharmacotherapy options in rheumatoid arthritisInvolvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.Nutritional considerations in pediatric inflammatory bowel disease.Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management.Potential food-drug interactions in patients with rheumatoid arthritis.The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.Impaired NFKBIE gene function decreases cellular uptake of methotrexate by down-regulating SLC19A1 expression in a human rheumatoid arthritis cell line.Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.A woman with rheumatoid arthritis whose condition did not improve during pregnancy.Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
P2860
Q24674942-AFC4985B-A40F-492D-AC82-36FB937AD4DDQ28390019-3C448800-ECB2-4AEE-8E84-6150EB9C4BABQ33725184-5681CE6C-4F77-4B3B-994B-0554D08A92F8Q33768874-147B8A75-E6A6-4915-86FD-3ECA74799FE8Q34389362-70AD8A6E-9CA7-47D7-B4AF-45D4A0C727E6Q35025094-BA8C7F8C-9F6C-46C6-A29A-31D71E178F90Q35827596-DD01E394-C5CC-4149-8572-F354C8F51AC9Q35953458-0A62A6F7-0A24-4083-9930-1E109357D201Q36013828-61734FF5-FDCD-462E-8275-CA914A122A7CQ36486374-2339ADA9-654F-4F22-B02B-F4B220C5E9FBQ37106758-84A9910A-EF82-4102-B363-9C7998B05906Q37148784-5FC65618-9B82-400B-B920-272E3DC36F68Q37763081-14330254-1836-410A-9DF4-BC5AAF75FC6DQ37943826-0757150C-B71E-4B95-B16E-FEF05ACFEF67Q38115004-837FE916-B109-48A7-8341-B9A2F0F2CA92Q38672339-F4D47ACE-4D1F-454A-AB44-62AF1797E8B3Q38818138-12586ACD-0DEA-4FDB-9E43-C6CE9A612277Q48899356-C5801187-B5EA-402A-BD7D-39D6AF85FEC9Q54166430-6D1D866F-2187-4ADE-9148-62C83FD27537Q55058941-86848B26-E97E-4426-9DD9-DC449612F751
P2860
Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Sulfasalazine is a potent inhi ...... exate in rheumatoid arthritis.
@en
type
label
Sulfasalazine is a potent inhi ...... exate in rheumatoid arthritis.
@en
prefLabel
Sulfasalazine is a potent inhi ...... exate in rheumatoid arthritis.
@en
P2093
P356
P1476
Sulfasalazine is a potent inhi ...... exate in rheumatoid arthritis.
@en
P2093
Ben A C Dijkmans
Gerrit Jansen
Ilan Ifergan
Joost van der Heijden
Rik J Scheper
Ruud Oerlemans
Willem F Lems
Yehuda G Assaraf
P304
P356
10.1002/ART.20375
P577
2004-07-01T00:00:00Z